Elevating Veterinary Healthcare: Innovations in Detection and Treatment of Drug Residues and Additives Through Biotechnological Advances
Introduction of Elevating Veterinary Healthcare
Concerning the rapidly developing sphere of veterinary medicine, it is crucial to use safe and effective remedies for animal diseases, which affects the quality of experimental results and the animal products used by people. Some of the principal techniques, derived from the progress in biotechnology, include the new anti-small molecule antibodies and small molecule competitive antigens ideal for the identification and overall treatment of veterinary drug residues and additives. These developments are important in the protection of animals’ health and the reliable supply of the food chain.
Comprehensive Overview of Veterinary Drug Residues and Additives
The residues of veterinary drugs and feed additives refer to a broad class of substances that are used in animals’ treatments and food, which may remain in the products. Some of these are the antibiotics, hormones and growth promoters all of which come with the complexity of affecting animal and human health in case of imbalance in their use and application.
Classifications and Significant Small Molecules
Antibiotics: Some of the important molecules like tetracycline, sulfonamide, and penicillin are used to control bacterial infections in animals. The constant supervision of their residues meet the increasing worries on antimicrobial resistance and food safety.
Hormones and Growth Promoters: Hormones like trenbolone and zeranol are used for enhancement of the growth rate in animals. Their residues ought to be strictly controlled as they are considered to be endocrine disruptors for the consumers.
Antiparasitics: Major treatments include IVOMEC, distributes avermectin, and PRZ Tokens; Praziquantel which has a vital role in combating parasitic diseases. The proper regulation of these substances in animal products is significant to promoting health standards as well as avoiding the occurrence of various health issues.
Diagnostic and Therapeutic Innovations
Diagnostics: The competency in terms of specificity and sensitivity for detection of veterinary drug residues came into the diagnostics with anti-small molecule antibodies. It also makes it possible to thoroughly screen animal products like tissue, milk, and eggs in a regulatory compliant standard and offer consumer protection.
Therapeutics: This use of small molecule competitive antigens is a complete innovation in the therapy strategy. These antigens work as decoys or inhibitors and have the ability to neutralise the ill effects of accumulated residues of the drugs therefore promoting safe veterinary practices and helping in delivering residue free animal produce.
Conclusion
Such advances in the application of essential biotechnological techniques in veterinary diagnostics and therapeutics can be regarded as a century leap in the animal healthcare and food safety. These make the use of anti-small molecule antibodies and the small molecule competitive antigens most essential in unravelling the situations involved in drug residues and additives to meet the safety standards of the modern world market.
Discover our high-tech biotechnological offerings that will help you revolutionalize veterinary medicine and overcome the most complex problems relating to veterinary drug residues and additives. Work with our technologies to enhance status in animal health and food safety, to promote animal welbeing and consumers’ health in the world.
According to the suggestion of Genemedi, we established antigens and antibodies for rare detection of various kinds of small molecules in veterinary drug residue plus additives. Our ELISA, Lateral Flow Immunoassay (LFIA), Colloidal Gold Immunochromatographic Assay, Chemiluminescent Immunoassay (CLIA), Turbidimetric Inhibition Immunoassay (TINIA), Immunonephelometry and Point-of-Care Testing (POCT) line of diagnostics represents the best tradition of accuracy and reliability which proves our unyielding effort for perfection.
Product List
| Cat No. | Small molecules (Chemicals, Antibiotics, Mycotoxins, Hormones, Drugs of Abuse, etc.) | Carrier-coupled antigen/immunogen (hapten-carrier conjugates) |
Anti-Hapten Antibody | Bioactivity validation | ELISA IC50 (ppb) |
Order |
| GMP-SMT-1 | Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings) | BSA-Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings); OVA-Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings) | Anti-Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings) mouse monoclonal antibody; Anti-Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-5 |  |
| GMP-SMT-2 | Sulfonamides Residue (SAs) (6-atom-rings) | BSA-Sulfonamides Residue (SAs) (6-atom-rings); OVA-Sulfonamides Residue (SAs) (6-atom-rings) | Anti-Sulfonamides Residue (SAs) (6-atom-rings) mouse monoclonal antibody; Anti-Sulfonamides Residue (SAs) (6-atom-rings) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-5 | |
| GMP-SMT-3 | Sulfadiazine(SD) | BSA-Sulfadiazine(SD); OVA-Sulfadiazine(SD) | Anti-Sulfadiazine(SD) mouse monoclonal antibody; Anti-Sulfadiazine(SD) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-5 | |
| GMP-SMT-4 | Sulfaquinoxaline (SQX) | BSA-Sulfaquinoxaline (SQX); OVA-Sulfaquinoxaline (SQX) | Anti-Sulfaquinoxaline (SQX) mouse monoclonal antibody; Anti-Sulfaquinoxaline (SQX) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-5 | Sulfamethazine(SM2) | BSA-Sulfamethazine(SM2); OVA-Sulfamethazine(SM2) | Anti-Sulfamethazine(SM2) mouse monoclonal antibody; Anti-Sulfamethazine(SM2) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-5 | |
| GMP-SMT-6 | Sulfadimethoxine(SMD) | BSA-Sulfadimethoxine(SMD); OVA-Sulfadimethoxine(SMD) | Anti-Sulfadimethoxine(SMD) mouse monoclonal antibody; Anti-Sulfadimethoxine(SMD) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-3 | |
| GMP-SMT-7 | Sulfachloropyrazine | BSA-Sulfachloropyrazine; OVA-Sulfachloropyrazine | Anti-Sulfachloropyrazine mouse monoclonal antibody; Anti-Sulfachloropyrazine human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.20 | |
| GMP-SMT-8 | Florfenicol(FF) | BSA-Florfenicol(FF); OVA-Florfenicol(FF) | Anti-Florfenicol(FF) mouse monoclonal antibody; Anti-Florfenicol(FF) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5.00 | |
| GMP-SMT-9 | Chloromycetin(CAP) | BSA-Chloromycetin(CAP); OVA-Chloromycetin(CAP) | Anti-Chloromycetin(CAP) mouse monoclonal antibody; Anti-Chloromycetin(CAP) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.3 | |
| GMP-SMT-10 | Chloramphenicol (TAP ) | BSA-Chloramphenicol (TAP ); OVA-Chloramphenicol (TAP ) | Anti-Chloramphenicol (TAP ) mouse monoclonal antibody; Anti-Chloramphenicol (TAP ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.3 | |
| GMP-SMT-11 | Chloramphenicols | BSA-Chloramphenicols; OVA-Chloramphenicols | Anti-Chloramphenicols mouse monoclonal antibody; Anti-Chloramphenicols human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.4 | |
| GMP-SMT-12 | Kanamycin(KAN) | BSA-Kanamycin(KAN); OVA-Kanamycin(KAN) | Anti-Kanamycin(KAN) mouse monoclonal antibody; Anti-Kanamycin(KAN) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-13 | Gentamicin(GM) | BSA-Gentamicin(GM); OVA-Gentamicin(GM) | Anti-Gentamicin(GM) mouse monoclonal antibody; Anti-Gentamicin(GM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-14 | Amikacin(AMK) | BSA-Amikacin(AMK); OVA-Amikacin(AMK) | Anti-Amikacin(AMK) mouse monoclonal antibody; Anti-Amikacin(AMK) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.1-0.2 | |
| GMP-SMT-15 | Streptomycin(STR) | BSA-Streptomycin(STR); OVA-Streptomycin(STR) | Anti-Streptomycin(STR) mouse monoclonal antibody; Anti-Streptomycin(STR) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-16 | Apramycin(APM) | BSA-Apramycin(APM); OVA-Apramycin(APM) | Anti-Apramycin(APM) mouse monoclonal antibody; Anti-Apramycin(APM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.00 | |
| GMP-SMT-17 | Spectinomycin(SPM) | BSA-Spectinomycin(SPM); OVA-Spectinomycin(SPM) | Anti-Spectinomycin(SPM) mouse monoclonal antibody; Anti-Spectinomycin(SPM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.50 | |
| GMP-SMT-18 | Tobramycin | BSA-Tobramycin; OVA-Tobramycin | Anti-Tobramycin mouse monoclonal antibody; Anti-Tobramycin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5.00 | |
| GMP-SMT-19 | Neomycin(NM) | BSA-Neomycin(NM); OVA-Neomycin(NM) | Anti-Neomycin(NM) mouse monoclonal antibody; Anti-Neomycin(NM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-21 | Lincomycin(LM) | BSA-Lincomycin(LM); OVA-Lincomycin(LM) | Anti-Lincomycin(LM) mouse monoclonal antibody; Anti-Lincomycin(LM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-22 | Pirlimycin(PIR) | BSA-Pirlimycin(PIR); OVA-Pirlimycin(PIR) | Anti-Pirlimycin(PIR) mouse monoclonal antibody; Anti-Pirlimycin(PIR) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-23 | Erythromycin(EM) | BSA-Erythromycin(EM); OVA-Erythromycin(EM) | Anti-Erythromycin(EM) mouse monoclonal antibody; Anti-Erythromycin(EM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5-10 | |
| GMP-SMT-24 | Avermectin(AVM) | BSA-Avermectin(AVM); OVA-Avermectin(AVM) | Anti-Avermectin(AVM) mouse monoclonal antibody; Anti-Avermectin(AVM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2.00 | |
| GMP-SMT-25 | Doramectin(DOR) | BSA-Doramectin(DOR); OVA-Doramectin(DOR) | Anti-Doramectin(DOR) mouse monoclonal antibody; Anti-Doramectin(DOR) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-3 | |
| GMP-SMT-26 | Tylosin(TYL) | BSA-Tylosin(TYL); OVA-Tylosin(TYL) | Anti-Tylosin(TYL) mouse monoclonal antibody; Anti-Tylosin(TYL) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-27 | Ivermectin (IVM) | BSA-Ivermectin (IVM); OVA-Ivermectin (IVM) | Anti-Ivermectin (IVM) mouse monoclonal antibody; Anti-Ivermectin (IVM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 3-4 | |
| GMP-SMT-28 | Tilmicosin(TIM) | BSA-Tilmicosin(TIM); OVA-Tilmicosin(TIM) | Anti-Tilmicosin(TIM) mouse monoclonal antibody; Anti-Tilmicosin(TIM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.60 | |
| GMP-SMT-29 | Tiamulin | BSA-Tiamulin; OVA-Tiamulin | Anti-Tiamulin mouse monoclonal antibody; Anti-Tiamulin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-3 | |
| GMP-SMT-30 | Acetylisovaleryl tylosin tartrate | BSA-Acetylisovaleryl tylosin tartrate; OVA-Acetylisovaleryl tylosin tartrate | Anti-Acetylisovaleryl tylosin tartrate mouse monoclonal antibody; Anti-Acetylisovaleryl tylosin tartrate human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 10.00 | |
| GMP-SMT-31 | Kitasamycin | BSA-Kitasamycin; OVA-Kitasamycin | Anti-Kitasamycin mouse monoclonal antibody; Anti-Kitasamycin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 20.00 | |
| GMP-SMT-32 | AlbendazoleI(ABZ) | BSA-AlbendazoleI(ABZ); OVA-AlbendazoleI(ABZ) | Anti-AlbendazoleI(ABZ) mouse monoclonal antibody; Anti-AlbendazoleI(ABZ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 9-10 | |
| GMP-SMT-35 | Natamycin(NTM) | BSA-Natamycin(NTM); OVA-Natamycin(NTM) | Anti-Natamycin(NTM) mouse monoclonal antibody; Anti-Natamycin(NTM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-36 | Salinomycin(SLM) | BSA-Salinomycin(SLM); OVA-Salinomycin(SLM) | Anti-Salinomycin(SLM) mouse monoclonal antibody; Anti-Salinomycin(SLM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-37 | Monensi(MON) | BSA-Monensi(MON); OVA-Monensi(MON) | Anti-Monensi(MON) mouse monoclonal antibody; Anti-Monensi(MON) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-38 | Vancomycin(VM) | BSA-Vancomycin(VM); OVA-Vancomycin(VM) | Anti-Vancomycin(VM) mouse monoclonal antibody; Anti-Vancomycin(VM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.8-1 | |
| GMP-SMT-39 | Albendazole metabolite(ABZ) | BSA-Albendazole metabolite(ABZ); OVA-Albendazole metabolite(ABZ) | Anti-Albendazole metabolite(ABZ) mouse monoclonal antibody; Anti-Albendazole metabolite(ABZ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-40 | Maduramicin | BSA-Maduramicin; OVA-Maduramicin | Anti-Maduramicin mouse monoclonal antibody; Anti-Maduramicin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-41 | Diclazuril | BSA-Diclazuril; OVA-Diclazuril | Anti-Diclazuril mouse monoclonal antibody; Anti-Diclazuril human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-1.5 | |
| GMP-SMT-42 | Toltrazuril (Methyl Triazine) | BSA-Toltrazuril (Methyl Triazine); OVA-Toltrazuril (Methyl Triazine) | Anti-Toltrazuril (Methyl Triazine) mouse monoclonal antibody; Anti-Toltrazuril (Methyl Triazine) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-43 | Levamisole | BSA-Levamisole; OVA-Levamisole | Anti-Levamisole mouse monoclonal antibody; Anti-Levamisole human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-44 | Mebendazole | BSA-Mebendazole; OVA-Mebendazole | Anti-Mebendazole mouse monoclonal antibody; Anti-Mebendazole human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5.00 | |
| GMP-SMT-45 | Triclabendazole | BSA-Triclabendazole; OVA-Triclabendazole | Anti-Triclabendazole mouse monoclonal antibody; Anti-Triclabendazole human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5.00 | |
| GMP-SMT-47 | Amprolium | BSA-Amprolium; OVA-Amprolium | Anti-Amprolium mouse monoclonal antibody; Anti-Amprolium human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 30.00 | |
| GMP-SMT-48 | tetracycline | BSA-tetracycline; OVA-tetracycline | Anti-tetracycline mouse monoclonal antibody; Anti-tetracycline human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-49 | Oxytetracycline(OTCs) | BSA-Oxytetracycline(OTCs); OVA-Oxytetracycline(OTCs) | Anti-Oxytetracycline(OTCs) mouse monoclonal antibody; Anti-Oxytetracycline(OTCs) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-50 | Chlortetracycline | BSA-Chlortetracycline; OVA-Chlortetracycline | Anti-Chlortetracycline mouse monoclonal antibody; Anti-Chlortetracycline human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-51 | Doxycycline | BSA-Doxycycline; OVA-Doxycycline | Anti-Doxycycline mouse monoclonal antibody; Anti-Doxycycline human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-52 | Tetracyclines | BSA-Tetracyclines; OVA-Tetracyclines | Anti-Tetracyclines mouse monoclonal antibody; Anti-Tetracyclines human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-53 | Norfloxacin | BSA-Norfloxacin; OVA-Norfloxacin | Anti-Norfloxacin mouse monoclonal antibody; Anti-Norfloxacin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-55 | Sarafloxacin(SAR) | BSA-Sarafloxacin(SAR); OVA-Sarafloxacin(SAR) | Anti-Sarafloxacin(SAR) mouse monoclonal antibody; Anti-Sarafloxacin(SAR) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-56 | Ofloxacin(OFX) | BSA-Ofloxacin(OFX); OVA-Ofloxacin(OFX) | Anti-Ofloxacin(OFX) mouse monoclonal antibody; Anti-Ofloxacin(OFX) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.5-1 | |
| GMP-SMT-59 | Danofloxacin | BSA-Danofloxacin; OVA-Danofloxacin | Anti-Danofloxacin mouse monoclonal antibody; Anti-Danofloxacin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-60 | Difloxacin | BSA-Difloxacin; OVA-Difloxacin | Anti-Difloxacin mouse monoclonal antibody; Anti-Difloxacin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-61 | Quinolones | BSA-Quinolones; OVA-Quinolones | Anti-Quinolones mouse monoclonal antibody; Anti-Quinolones human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-62 | Ampicillin (Ampicillin, Amoxicillin,AMP) | BSA-Ampicillin (Ampicillin, Amoxicillin,AMP); OVA-Ampicillin (Ampicillin, Amoxicillin,AMP) | Anti-Ampicillin (Ampicillin, Amoxicillin,AMP) mouse monoclonal antibody; Anti-Ampicillin (Ampicillin, Amoxicillin,AMP) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.1-0.2 | |
| GMP-SMT-63 | Penicillin G | BSA-Penicillin G; OVA-Penicillin G | Anti-Penicillin G mouse monoclonal antibody; Anti-Penicillin G human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.1-0.2 | |
| GMP-SMT-64 | Ceftiofur(CEF) | BSA-Ceftiofur(CEF); OVA-Ceftiofur(CEF) | Anti-Ceftiofur(CEF) mouse monoclonal antibody; Anti-Ceftiofur(CEF) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-65 | Cefquinome(CEQ) | BSA-Cefquinome(CEQ); OVA-Cefquinome(CEQ) | Anti-Cefquinome(CEQ) mouse monoclonal antibody; Anti-Cefquinome(CEQ) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
| GMP-SMT-66 | Cephalosporin(CEP) | BSA-Cephalosporin(CEP); OVA-Cephalosporin(CEP) | Anti-Cephalosporin(CEP) mouse monoclonal antibody; Anti-Cephalosporin(CEP) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
| GMP-SMT-67 | Cephalexin(CEX) | BSA-Cephalexin(CEX); OVA-Cephalexin(CEX) | Anti-Cephalexin(CEX) mouse monoclonal antibody; Anti-Cephalexin(CEX) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-68 | Hygromycin B(HMB) | BSA-Hygromycin B(HMB); OVA-Hygromycin B(HMB) | Anti-Hygromycin B(HMB) mouse monoclonal antibody; Anti-Hygromycin B(HMB) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
| GMP-SMT-69 | Bacitracin(BCT) | BSA-Bacitracin(BCT); OVA-Bacitracin(BCT) | Anti-Bacitracin(BCT) mouse monoclonal antibody; Anti-Bacitracin(BCT) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-70 | Polymyxin B(PMB) | BSA-Polymyxin B(PMB); OVA-Polymyxin B(PMB) | Anti-Polymyxin B(PMB) mouse monoclonal antibody; Anti-Polymyxin B(PMB) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 10-20 | |
| GMP-SMT-72 | metoclopramide | BSA-metoclopramide; OVA-metoclopramide | Anti-metoclopramide mouse monoclonal antibody; Anti-metoclopramide human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.25 | |
| GMP-SMT-73 | Trimethoprim(TMP) | BSA-Trimethoprim(TMP); OVA-Trimethoprim(TMP) | Anti-Trimethoprim(TMP) mouse monoclonal antibody; Anti-Trimethoprim(TMP) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.20 | |
| GMP-SMT-74 | Polymyxin E(PME) | BSA-Polymyxin E(PME); OVA-Polymyxin E(PME) | Anti-Polymyxin E(PME) mouse monoclonal antibody; Anti-Polymyxin E(PME) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-75 | Cloxacillin | BSA-Cloxacillin; OVA-Cloxacillin | Anti-Cloxacillin mouse monoclonal antibody; Anti-Cloxacillin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 15.00 | |
| GMP-SMT-76 | Oxacillin | BSA-Oxacillin; OVA-Oxacillin | Anti-Oxacillin mouse monoclonal antibody; Anti-Oxacillin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 20.00 | |
| GMP-SMT-77 | Nitrofurazone metabolite (CPSEM) | BSA-Nitrofurazone metabolite (CPSEM); OVA-Nitrofurazone metabolite (CPSEM) | Anti-Nitrofurazone metabolite (CPSEM) mouse monoclonal antibody; Anti-Nitrofurazone metabolite (CPSEM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.20 | |
| GMP-SMT-79 | Furazolidone metabolite (CPAOZ) | BSA-Furazolidone metabolite (CPAOZ); OVA-Furazolidone metabolite (CPAOZ) | Anti-Furazolidone metabolite (CPAOZ) mouse monoclonal antibody; Anti-Furazolidone metabolite (CPAOZ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-80 | Furaltadone metabolite (CPAMOZ) | BSA-Furaltadone metabolite (CPAMOZ); OVA-Furaltadone metabolite (CPAMOZ) | Anti-Furaltadone metabolite (CPAMOZ) mouse monoclonal antibody; Anti-Furaltadone metabolite (CPAMOZ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.30 | |
| GMP-SMT-85 | Benzoic Acid(BZA) | BSA-Benzoic Acid(BZA); OVA-Benzoic Acid(BZA) | Anti-Benzoic Acid(BZA) mouse monoclonal antibody; Anti-Benzoic Acid(BZA) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
| GMP-SMT-101 | Nitenpyram(NIT) | BSA-Nitenpyram(NIT); OVA-Nitenpyram(NIT) | Anti-Nitenpyram(NIT) mouse monoclonal antibody; Anti-Nitenpyram(NIT) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-3 | |
| GMP-SMT-111 | Arermectin | BSA-Arermectin; OVA-Arermectin | Anti-Arermectin mouse monoclonal antibody; Anti-Arermectin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.3 | |
| GMP-SMT-132 | Ractopamine(RCT) | BSA-Ractopamine(RCT); OVA-Ractopamine(RCT) | Anti-Ractopamine(RCT) mouse monoclonal antibody; Anti-Ractopamine(RCT) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.10 | |
| GMP-SMT-134 | Salbutamol(SAL) | BSA-Salbutamol(SAL); OVA-Salbutamol(SAL) | Anti-Salbutamol(SAL) mouse monoclonal antibody; Anti-Salbutamol(SAL) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.25 | |
| GMP-SMT-137 | Clorprenaline(CLP) | BSA-Clorprenaline(CLP); OVA-Clorprenaline(CLP) | Anti-Clorprenaline(CLP) mouse monoclonal antibody; Anti-Clorprenaline(CLP) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-138 | CIMATEROL | BSA-CIMATEROL; OVA-CIMATEROL | Anti-CIMATEROL mouse monoclonal antibody; Anti-CIMATEROL human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.4 | |
| GMP-SMT-142 | Olaquindox(OLA) | BSA-Olaquindox(OLA); OVA-Olaquindox(OLA) | Anti-Olaquindox(OLA) mouse monoclonal antibody; Anti-Olaquindox(OLA) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.8-1 | |
| GMP-SMT-143 | Olaquindox metabolite(MQCA) | BSA-Olaquindox metabolite(MQCA); OVA-Olaquindox metabolite(MQCA) | Anti-Olaquindox metabolite(MQCA) mouse monoclonal antibody; Anti-Olaquindox metabolite(MQCA) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
Q&A
Q1: What is anti-Small molecule antibodies and how do they affect veterinary medicine?
A1: Anti-small molecule antibodies are specific synthetic proteins for coupling small molecules, for example, remainder of veterinary drugs. They are essential to the veterinary healthcare facility because they help in indicating the residues of drugs in animal products, which in turn assist in ascertaining the safety of the products in relation to set health standards.
Q2: In the treatment of drug residues, how do small molecule competitive antigens cause any consideration?
A2: Small molecule competitive antigens work by having a structure similar to the drug residues; this makes them act as bait to replace residues that are bound to antibodies or receptors. It assists in reducing the impacts of drug residues in animals to make veterinary practices safer and animal-derived products healthy.
Q3: What kinds of veterinary medicine residues are frequently analyzed?
A3: Example of the monitored veterinary drugs include antibiotics (the likes of tetracycline, penicillin), hormones and growth enhancing substances (trenbolone, zeranol) and the antiparasitic agents (ivermectin). Supervision of these residues is crucial to check the spread of antimicrobial resistances, food safety and consumers’ health.
Q4: From the following list of diagnostic methods, which of them are employed in the analysis of veterinary drug residues?
A4: The techniques adapted to detect Veterinary Drug Residues are Enzyme-Linked Immunosorbent Assay (ELISA), Lateral Flow Immunoassay (LFIA), Colloidal Gold Immunochromatographic Assay, Chemiluminescent Immunoassay (CLIA) and Point of Care Testing (POCT). These method present a sensitivity and specificity to detect residues in animal tissues, milk as well as eggs.
Q5: Residues of veterinary drugs are important to be detected for the protection of public health since it prevents the introduction of the dangerous residues into food chain, minimizes the threats of antimicrobial resistance and guarantees the safety of products of animal origin. It has been established that proper detection and handling of these residues is central to retention of consumers’ confidence on the safety of the food they consume as well as safety of animal and human health.
Facebook
LinkedIn
Twitter
